Last updated 2026-06-18
- Acquired by Revium Rx, Feb 2025
Total raised
—
Stage
Acquired
Founded
2021
Headcount
9
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
LipoVation’s core technology was conceptualized by Prof. Yehezkel Barenholz, a world-renowned scientist and the inventor of Doxil, the first FDA-approved liposomal chemotherapy drug, widely used in the treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma.
Q&A
- What is Lipovation's primary focus?
- Lipovation specializes in Lipid-based Nano/micro Particle Medicines.
- Who conceptualized Lipovation's core technology?
- Lipovation's core technology was conceptualized by Prof. Yehezkel Barenholz, the inventor of Doxil, an FDA-approved liposomal chemotherapy drug.
- When was Lipovation founded?
- Lipovation was founded in February 2021.
- What is the current status of Lipovation?
- Lipovation was acquired by Revium Rx in February 2025 and is currently inactive.
- How many employees does Lipovation have?
- Lipovation has 1-10 employees.
- Where is Lipovation headquartered?
- Lipovation is headquartered in Herzliya, Israel.
- Who is the CEO of Lipovation?
- The CEO of Lipovation is David Akunis.
- Who is the CTO of Lipovation?
- The CTO of Lipovation is Erez Koren.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/3738990 |
Identifiers & details
| Founded | 2021-2 |
|---|---|
| Employees (exact) | 9 |
| Status reason | Acquired (Inactive) by Revium Rx on Feb 2025 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Revium Rx 2025-02